Enclomiphene Citrate

Quick Reference Card

Overview / What Is Enclomiphene Citrate?

The Basics

Enclomiphene citrate is one half of a medication you may already know: clomiphene (Clomid). Clomiphene has been used for decades, primarily to help women ovulate. It contains two mirror-image molecules, called isomers, that do very different things. The trans-isomer, enclomiphene, is the component that blocks estrogen receptors and stimulates the body to produce more testosterone. The cis-isomer, zuclomiphene, actually mimics estrogen in some tissues and is believed to cause many of clomiphene's unwanted side effects, including mood changes, decreased libido, and visual disturbances.

Enclomiphene isolates the beneficial isomer and removes the problematic one. The idea is straightforward: by blocking estrogen receptors in the brain, enclomiphene tricks the pituitary gland into thinking estrogen levels are low. The pituitary responds by releasing more LH and FSH, which signal the testes to produce more testosterone and sperm. Unlike testosterone replacement therapy, which shuts down this signaling pathway and suppresses sperm production, enclomiphene works with the body's natural hormone production system.

This distinction matters most for men who want to address low testosterone without sacrificing fertility. For men with secondary hypogonadism (where the problem originates in the brain's signaling, not in the testes themselves), enclomiphene offers a way to raise testosterone levels while keeping sperm production intact. For men with primary hypogonadism (where the testes themselves are damaged or dysfunctional), enclomiphene is generally ineffective because the testes cannot respond even when signaled.

There is an important caveat: enclomiphene is not FDA-approved. The pharmaceutical company that developed it (Repros Therapeutics, under the brand name Androxal) pursued FDA approval for over a decade but was ultimately unsuccessful. The FDA's primary concern was that while enclomiphene reliably raised testosterone numbers on lab tests, the clinical trials did not convincingly demonstrate that patients experienced meaningful improvement in symptoms like fatigue, low libido, and mood changes [1]. This concern has been echoed by many patients in real-world use, who report excellent lab results without corresponding subjective improvement. The drug is currently available only through compounding pharmacies with a prescription.

The Science

Enclomiphene citrate ((E)-2-(p-(2-Chloro-1,2-Diphenylvinyl)phenoxy)triethylamine) is the trans-stereoisomer of clomiphene citrate. Clomiphene citrate consists of approximately 62% enclomiphene (trans) and 38% zuclomiphene (cis), with zuclomiphene demonstrating predominantly estrogenic activity and enclomiphene demonstrating predominantly anti-estrogenic activity at the hypothalamic-pituitary level [2][3].

The rationale for isolating enclomiphene from the racemic mixture emerged from pharmacological studies demonstrating that zuclomiphene has a markedly longer half-life (approximately 30 days) compared to enclomiphene (approximately 10 hours), resulting in accumulation of an estrogen agonist with prolonged administration of clomiphene citrate [4]. This zuclomiphene accumulation has been hypothesized to contribute to the estrogenic side effects observed with clomiphene therapy, including decreased libido, mood disturbance, and visual symptoms [5].

Repros Therapeutics pursued enclomiphene (Androxal) through Phase I, II, and III clinical development for secondary hypogonadism in men. Phase III trials (Kim et al., 2016, n=265) demonstrated that enclomiphene at 12.5 mg and 25 mg daily raised testosterone into the normal range while preserving sperm counts, in contrast to topical testosterone which suppressed sperm density by 32.8-56.6% [6]. Despite meeting primary laboratory endpoints, the FDA issued a Complete Response Letter in December 2015, stating that the clinical trial design was no longer adequate to demonstrate clinical benefit beyond testosterone normalization [7]. The European Medicines Agency (EMA) similarly declined to approve enclomiphene (EnCyzix). The manufacturer discontinued development in 2021.

Medical / Chemical Identity

Mechanism of Action / Pathophysiology

The Basics

To understand how enclomiphene works, picture your hormone system as a thermostat. Your brain constantly monitors estrogen levels (which are partly produced from testosterone). When estrogen is at the right level, the brain says "we have enough testosterone, no need to make more." When estrogen drops, the brain says "we need more testosterone" and sends signals (LH and FSH) down to the testes to ramp up production.

Enclomiphene works by blocking the estrogen sensors in your brain. Even though your estrogen levels may be normal, the brain cannot detect them because enclomiphene is sitting in the way. The brain interprets this as "estrogen is low, we need more testosterone" and starts sending stronger signals. Your testes respond by making more testosterone and more sperm.

This is fundamentally different from taking testosterone directly. When you inject or apply testosterone, your brain detects the elevated hormone levels and shuts down its own signaling. Your testes receive no stimulation and gradually shrink and stop producing sperm. Enclomiphene does the opposite: it amplifies the brain's signals, keeping the testes active and productive.

However, there is a trade-off. Because enclomiphene blocks estrogen receptors, it may also block estrogen's beneficial effects in other tissues. Estrogen plays important roles in men, including supporting bone health, brain function, mood, sexual desire, and cardiovascular health. Some men who take enclomiphene find that while their testosterone numbers look excellent on paper, they do not feel the full benefit because estrogen signaling is partially blocked in tissues throughout the body. This "numbers vs symptoms" disconnect is a recognized phenomenon with SERM therapy and an important consideration when evaluating whether enclomiphene is the right choice.

The Science

Enclomiphene exerts its pharmacological effect through competitive antagonism of estrogen receptor alpha (ERa) at the hypothalamic and anterior pituitary level. By displacing 17-beta-estradiol from ERa in gonadotrope cells, enclomiphene disrupts the negative feedback loop that normally suppresses gonadotropin-releasing hormone (GnRH) pulsatility and subsequent LH and FSH secretion [2][8].

The resulting increase in LH stimulates Leydig cell testosterone synthesis, while FSH elevation supports Sertoli cell function and spermatogenesis. This mechanism distinguishes enclomiphene from exogenous testosterone, which suppresses the hypothalamic-pituitary-gonadal (HPG) axis via negative feedback, leading to reduced intratesticular testosterone concentrations and spermatogenic arrest [6].

Unlike zuclomiphene (the cis-isomer), which demonstrates mixed agonist-antagonist activity at estrogen receptors (with predominant agonist activity in certain tissues), enclomiphene functions as a relatively pure estrogen receptor antagonist at the hypothalamic-pituitary axis [3]. This selective antagonism is thought to underlie enclomiphene's more favorable side effect profile compared to racemic clomiphene, particularly with respect to estrogenic adverse events such as mood disturbance, decreased libido, and gynecomastia [5].

The requirement for intact HPG axis function is absolute. In primary hypogonadism (testicular failure), the testes are unable to respond to increased gonadotropin stimulation regardless of LH and FSH elevation. Enclomiphene is therefore indicated only in secondary (hypogonadotropic) or functional hypogonadism where the hypothalamic-pituitary signaling deficit is the primary pathology [4][9].

Pathway & System Visualization

Pharmacokinetics / Hormone Physiology

The Basics

Enclomiphene is taken as a daily oral pill, which makes it one of the simplest hormone-related medications to administer. After you swallow a dose, it reaches peak blood levels within 2 to 3 hours. It has a half-life of about 10 hours, meaning half the drug is cleared from your body in that time. This relatively short duration is why daily dosing is typically recommended.

Compare this to zuclomiphene (the other half of clomiphene/Clomid), which has a half-life of approximately 30 days. This means zuclomiphene accumulates in your body over weeks and months, potentially building up estrogenic effects long after the anti-estrogenic benefits have peaked. Enclomiphene avoids this problem by being cleared quickly.

Despite the short drug half-life, enclomiphene's effects on LH and testosterone persist longer than you might expect. Studies have shown that elevated LH and testosterone levels continue for at least one week after stopping the drug [4]. This suggests that the hormonal cascade enclomiphene triggers has momentum beyond the drug's direct presence in your bloodstream.

One notable pharmacokinetic finding: a non-dose-dependent steady-state level was reached at the 25 mg/day dose, meaning going above 25 mg daily did not proportionally increase drug levels [4]. This has practical implications for dosing: more is not necessarily better.

The Science

Enclomiphene demonstrates rapid oral absorption with a time to maximum concentration (Tmax) of 2-3 hours following oral administration. First-order elimination follows, with a terminal half-life of approximately 10 hours. Steady-state drug levels are achieved with daily dosing, with a non-dose-dependent plateau at the 25 mg/day dose [4][10].

In the pharmacodynamic study by Wiehle et al. (2013), 48 men with secondary hypogonadism (total T <350 ng/dL, LH <12 IU/L) received enclomiphene at 6.25 mg, 12.5 mg, or 25 mg daily versus transdermal testosterone (AndroGel 1%) for 6 weeks. Peak serum enclomiphene concentrations did not temporally correlate with LH secretion peaks, suggesting that the drug's pharmacodynamic effect is not acutely tied to plasma drug levels but rather to sustained receptor occupancy [4].

After 6 weeks of continuous dosing, mean total testosterone levels by dose group were: 6.25 mg: 13.6 nmol/L; 12.5 mg: 14.8 nmol/L; 25 mg: 20.3 nmol/L (604 +/- 160 ng/dL). The 25 mg group achieved comparable testosterone levels to the transdermal testosterone group (500 +/- 278 ng/dL, p=0.23), but with increased rather than suppressed LH and FSH [4][11].

Enclomiphene did not significantly affect thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), cortisol, lipid profiles, or bone turnover markers. Both transdermal testosterone and enclomiphene decreased insulin-like growth factor 1 (IGF-1) levels, with greater suppression in the enclomiphene groups [4]. The clinical significance of this IGF-1 reduction remains uncertain.

Research & Clinical Evidence

The Basics

Enclomiphene has been studied in several clinical trials, mostly sponsored by its manufacturer, Repros Therapeutics. The research consistently shows two things: first, enclomiphene reliably raises testosterone levels into the normal range in men with secondary hypogonadism; second, it preserves sperm production while doing so. These two findings are the foundation of enclomiphene's clinical case.

The largest study enrolled 265 overweight men aged 18-60 with secondary hypogonadism. Men taking enclomiphene achieved normal testosterone levels while maintaining their sperm counts. Men taking testosterone gel, by contrast, saw sperm counts drop by 33% to 57% [6]. This fertility preservation advantage is enclomiphene's strongest clinical argument.

Where the evidence falls short is in demonstrating that higher testosterone numbers translate into feeling better. The FDA specifically noted that the clinical trials did not convincingly demonstrate meaningful improvement in symptoms like fatigue, low libido, and cognitive issues [1]. This gap between lab improvements and symptom relief is a genuine limitation that patients should understand before starting treatment.

A 2025 meta-analysis of 10 randomized controlled trials (819 patients total) confirmed that SERM therapy (clomiphene and enclomiphene combined) significantly increases total testosterone by approximately 274 ng/dL compared to placebo, while maintaining higher LH and FSH levels than testosterone gel [12]. A 2024 retrospective study comparing 66 men who transitioned from clomiphene to enclomiphene found that enclomiphene produced a comparable testosterone increase (median 166 ng/dL) with significantly fewer side effects, particularly decreased libido (8.6% vs 33.3%), reduced energy (5.2% vs 16.7%), and mood changes (0% vs 9.1%) [5].

The Science

The clinical evidence base for enclomiphene in male hypogonadism spans Phase I through Phase III development. Key trials:

Phase II (Wiehle et al., 2013, n=44): Randomized, single-blind study comparing three enclomiphene doses (6.25 mg, 12.5 mg, 25 mg) to transdermal testosterone. All enclomiphene doses increased total testosterone, LH, and FSH. The 25 mg dose achieved C0hr testosterone of 604 +/- 160 ng/dL versus 500 +/- 278 ng/dL for transdermal T (p=0.23). LH and FSH increased with enclomiphene while decreasing with transdermal testosterone [4].

Phase IIb (Wiehle et al., 2014, n=124 enrolled, 73 completed): Randomized, double-blind, placebo-controlled. Inclusion: two morning T <250 ng/dL. Enclomiphene 12.5 mg increased T from 217 to 472 ng/dL (p<0.05); 25 mg from 210 to 406 ng/dL (p<0.05). LH increased from 5.3 to 11.9 mIU/mL with 25 mg (p<0.05). Sperm density was preserved across all enclomiphene groups [13].

Phase III (Kim et al., 2016, n=265): Two pooled randomized, double-blind, placebo-controlled studies in overweight men 18-60 with secondary hypogonadism. Enclomiphene maintained sperm counts (+11.7% and +15.2% change) versus testosterone gel (-56.6% and -32.8%). Both enclomiphene and testosterone gel normalized serum testosterone [6].

Saffati et al. (2024, n=66): Retrospective study at Baylor College of Medicine. Patients on clomiphene transitioned to enclomiphene. Enclomiphene: median T increase 166 ng/dL, E2 change -5.92 pg/mL. Clomiphene: median T increase 98 ng/dL, E2 change +17.50 pg/mL (p=0.001). Overall adverse events: 13.8% enclomiphene vs 47% clomiphene (p=0.001). OR for adverse events with enclomiphene: 0.18 (95% CI: 0.07-0.44, p=0.02) [5].

Meta-analysis (Hohl et al., 2025, 10 RCTs, 819 patients): SERM therapy (clomiphene/enclomiphene) vs placebo: total testosterone increase MD 273.76 ng/dL (95% CI: 191.87-355.66, p<0.01); LH increase MD 4.66 IU/L; FSH increase MD 4.59 IU/L. SERM therapy comparable to T gel for testosterone increases but with preserved gonadotropin levels [12].

Evidence & Effectiveness Matrix

Categories scored: 12
Categories with community data: 10
Categories not scored (insufficient data): Anxiety & Stress Response, Body Fat & Composition, Bone Health, Cardiovascular Health, Metabolic Health, Sleep Quality, Fluid Retention & Edema, Prostate Health

Benefits & Therapeutic Effects

The Basics

Enclomiphene's benefits center on two key advantages over traditional testosterone replacement therapy.

The first and most significant benefit is fertility preservation. When you take testosterone directly, your body's natural testosterone production shuts down, and sperm production often drops to zero or near-zero within a few months. Enclomiphene works in the opposite direction: by stimulating your own system rather than replacing it, sperm production is maintained. For men who want to address low testosterone without risking their ability to have children, this is a substantial advantage. Clinical trials showed that men on enclomiphene maintained or slightly increased their sperm counts, while men on testosterone gel saw declines of 33% to 57% [6].

The second benefit is the avoidance of polycythemia, the dangerous thickening of the blood that is one of TRT's most common and potentially serious side effects. Because enclomiphene raises testosterone through endogenous production (at physiological, not supraphysiological levels), it does not stimulate red blood cell production the way exogenous testosterone does. Studies show minimal hematocrit changes with enclomiphene [5].

Additional reported benefits include oral administration (no injections, no skin transfer risk), preservation of testicular size (unlike TRT, which causes testicular atrophy), and the potential for recovery of natural hormone production after discontinuation (since the HPG axis was never suppressed).

Where enclomiphene's benefits are less certain is in symptom relief. While some men report meaningful improvement in energy, libido, and mood, others find that raising testosterone numbers does not translate into feeling better. This variability appears to be genuinely individual, and the lack of consistent symptomatic improvement was the primary reason the FDA declined to approve the drug.

The Science

The primary evidence-based benefits of enclomiphene citrate are:

Spermatogenesis preservation: Phase III data (Kim et al., 2016) demonstrated sperm density changes of +11.7% and +15.2% with enclomiphene versus -56.6% and -32.8% with topical testosterone over 4 months (p<0.001) [6]. This represents the drug's strongest clinical advantage and its primary differentiation from exogenous testosterone.

Gonadotropin maintenance: Unlike exogenous testosterone, which suppresses LH and FSH (often to undetectable levels), enclomiphene increases LH and FSH. In the Phase IIb trial, 25 mg enclomiphene increased LH from 5.3 to 11.9 mIU/mL and FSH from 9.4 to 14.9 mIU/mL (p<0.05) [13]. This maintains intratesticular testosterone at levels sufficient for spermatogenesis.

Hematologic safety: Saffati et al. (2024) reported median hematocrit change of 0% with enclomiphene versus 0.4% with clomiphene (p=0.85, both non-significant) [5]. This is a meaningful safety advantage over injectable testosterone, which can increase hematocrit above the 54% threshold requiring intervention.

Reduced estrogenic side effects vs clomiphene: By eliminating zuclomiphene (which has estrogen agonist activity and a 30-day half-life), enclomiphene demonstrates significantly fewer estrogenic adverse effects. Saffati et al. found overall adverse events at 13.8% versus 47% for clomiphene (p=0.001), with specific reductions in decreased libido, mood changes, and energy complaints [5].

Risks, Side Effects & Safety

The Basics

Enclomiphene's side effect profile is generally milder than both exogenous testosterone and racemic clomiphene. However, it is not without risks, and the limited long-term safety data means some effects may not yet be fully understood.

The most commonly reported side effects from clinical trials are headache (1.6%), hot flushes (1.1%), nausea (1.0%), muscle spasms (0.9%), and dizziness (0.7%) [11]. These are generally mild and tend to occur early in treatment.

A more subtle but important concern is the estrogen receptor blockade effect. By blocking estrogen receptors, enclomiphene may reduce the beneficial effects of estrogen in the brain, bones, and cardiovascular system. Estrogen plays essential roles in male health, and chronic blockade could theoretically affect bone density, mood, and cardiovascular protection over time. No long-term studies have evaluated these risks.

Estradiol levels may paradoxically rise during enclomiphene treatment. As testosterone increases, more of it is converted to estradiol through aromatization (especially in men with higher body fat). This is not a direct effect of enclomiphene but rather a consequence of elevated testosterone. Some men require aromatase inhibitor co-administration to manage elevated E2 symptoms.

Regarding cardiovascular safety, the TRAVERSE trial (the landmark cardiovascular safety study for TRT) evaluated exogenous testosterone gel, not enclomiphene. No cardiovascular safety trial has been conducted for enclomiphene specifically. A safety review of 11 prospective trials (953 enclomiphene patients, 290 placebo, 130 T gel) noted thromboembolic events comparable to those seen with testosterone therapies [1]. Without dedicated cardiovascular outcome data, definitive cardiovascular risk statements cannot be made for enclomiphene.

Visual side effects are a known concern with clomiphene use, and while enclomiphene is thought to have a lower risk (due to shorter half-life and absence of zuclomiphene), the possibility of visual disturbances (including blurred vision and, rarely, cataracts with long-term use) should be discussed with a provider. One community user reported developing cataracts at age 44 after 5 years of clomiphene use, though causality was uncertain.

The most important contraindication is primary hypogonadism. Enclomiphene cannot stimulate testosterone production from testes that are unable to respond. Using enclomiphene in primary hypogonadism will raise LH and FSH further without producing testosterone, potentially causing frustration and delay in appropriate treatment.

The Science

Common adverse effects (from Phase II/III trials and BSSM position statement [11]):

• Headache: 1.6%
• Hot flushes: 1.1%
• Nausea: 1.0%
• Muscle spasms: 0.9%
• Dizziness: 0.7%
• Elevated estradiol (secondary to increased aromatization of endogenously produced testosterone)

Comparative safety (Saffati et al., 2024 [5]):

Regression analysis: OR for adverse events with enclomiphene 0.18 (95% CI: 0.07-0.44, p=0.02) [5].

Cardiovascular considerations: No dedicated cardiovascular outcomes trial exists for enclomiphene. The TRAVERSE trial (n=5,246) evaluated exogenous testosterone gel in men 45-80 with cardiovascular risk factors, finding non-inferiority for MACE (HR 0.96, 95% CI: 0.78-1.17) [14]. Whether these findings extend to SERM-induced endogenous testosterone elevation is unknown. Thromboembolic events were noted in pooled enclomiphene trial data at rates comparable to testosterone therapies [1].

Contraindications:

• Primary hypogonadism (testicular failure)
• History of liver disease
• Uncontrolled adrenal or thyroid dysfunction
• Certain pituitary conditions (where SERM mechanism would be ineffective or dangerous)
• Allergy to clomiphene or enclomiphene
• Known thromboembolic disorder (relative contraindication)

Being informed about potential risks is important. Being able to track and document any side effects you actually experience is what turns awareness into safety. Doserly lets you log side effects as they happen, with timestamps and severity ratings, so nothing falls through the cracks between appointments.

If you're noticing acne, water retention, mood changes, or any other shift, having a documented timeline helps your provider distinguish between expected adjustment effects and signals that warrant a protocol change. The app also tracks your hematocrit and PSA values over time, alerting you when levels approach thresholds that need attention.

Dosing & Treatment Protocols

The Basics

Enclomiphene dosing is still evolving because the drug never received FDA approval, meaning there are no official prescribing guidelines. What we know comes from clinical trial protocols and real-world prescribing patterns at men's health clinics.

Clinical trials studied three doses: 6.25 mg, 12.5 mg, and 25 mg, all taken once daily by mouth. The 25 mg dose produced the highest testosterone levels (approximately 604 ng/dL after 6 weeks), while the 12.5 mg dose also produced meaningful increases (approximately 472 ng/dL after 3 months) [4][13]. The BSSM recommends starting at 6.25 mg daily, increasing weekly as tolerated up to 25 mg daily, with the option to go up to 50 mg daily for inadequate response [11].

In practice, dosing varies considerably. Some men take enclomiphene daily, others every other day, and some follow intermittent protocols (such as 3 days on, 2 days off). The community has observed that continuous daily dosing may lead to estrogen receptor desensitization over time, and some clinicians recommend periodic breaks or lower-frequency dosing.

A common starting protocol at men's health clinics is 12.5 mg daily or every other day, with lab work at 4-6 weeks to assess response. Dose adjustments are made based on total testosterone, free testosterone, estradiol, LH, and FSH levels, as well as symptom response.

One important consideration: testosterone onset is relatively quick. Studies show measurable testosterone increases within 14 days of starting enclomiphene [10]. However, full steady-state effects and symptom assessment typically require 4-6 weeks of consistent use.

The Science

Clinical trial dosing protocols:

BSSM dosing recommendation [11]:

• Start: 6.25 mg daily
• Titrate: Increase weekly as tolerated up to 25 mg daily
• Maximum: 50 mg daily (for inadequate clinical or biochemical response)

Monitoring schedule:

• Baseline labs: Total T (two morning draws), free T, LH, FSH, estradiol, SHBG, CBC with hematocrit, semen analysis (if fertility is a goal)
• Follow-up at 4-6 weeks: Total T, free T, LH, FSH, estradiol
• Ongoing: Every 3-6 months (total T, free T, estradiol, hematocrit, LH, FSH)
• Semen analysis: If fertility preservation is the primary indication, repeat at 3-6 months

Getting the dosing right often takes time and fine-tuning with your provider. Keeping an accurate record of what you're actually taking, doses, frequency, and any adjustments, makes that process smoother. Doserly tracks your enclomiphene doses alongside everything else in your health stack, so your full protocol is always in one place.

Never wonder whether you took your dose today or when your last lab draw was. The app logs every dose with a timestamp and sends reminders when your next one is due, helping you maintain the consistency that makes SERM therapy most effective and keeps your response predictable.

What to Expect (Timeline)

• Days 1-7: Enclomiphene begins raising LH and FSH within days. Most men notice no subjective changes in the first week. Some report mild headache. Testosterone levels begin to rise measurably within 14 days [10].
• Weeks 2-4: Testosterone levels continue climbing toward steady state. Some men report early improvements in energy, mood, or libido during this period. Others notice no change. Estradiol may begin rising as increased testosterone aromatizes. This is often the period when initial enthusiasm is highest.
• Months 1-3: Most clinical trials assessed outcomes at this point. Testosterone should be in the target range for responders. Libido, energy, and mood effects (if they occur) typically manifest during this window. Some men report a "honeymoon" phase of significant subjective improvement. Sperm counts remain stable or increase. Lab work at 4-6 weeks and again at 3 months helps guide dosing.
• Months 3-6: This is the critical evaluation period. Men who are going to benefit symptomatically from enclomiphene generally know by this point. Some users report that initial improvements plateau or diminish. Estradiol management may become important if levels continue rising. Body composition changes, if any, are modest compared to exogenous TRT.
• Months 6-12: Long-term data is limited. Some community users report sustained benefit; others describe a "taper-off" effect where early improvements fade. The BSSM recommends ongoing monitoring and reassessment. If symptomatic benefit has not materialized by this point, a conversation with your provider about alternative approaches (including TRT with fertility preservation strategies like HCG) is appropriate.
• Ongoing: Long-term safety data beyond 6 months does not exist from controlled trials. Men who continue enclomiphene indefinitely should have regular lab monitoring and periodic reassessment of the risk-benefit balance.

Fertility Preservation & HPG Axis

Fertility preservation is enclomiphene's primary clinical advantage and the reason most men choose it over exogenous testosterone.

How exogenous testosterone suppresses fertility: When you take testosterone by injection, gel, or other route, your brain detects elevated hormone levels and drastically reduces its production of LH and FSH. Without LH stimulation, the Leydig cells in your testes produce very little testosterone locally. Without FSH, the Sertoli cells cannot support sperm production. Intratesticular testosterone concentrations (normally 40-100 times higher than blood levels) drop to near-serum levels, and spermatogenesis arrests. Approximately 40-60% of men on TRT achieve azoospermia (zero sperm) by 6 months [14].

How enclomiphene preserves fertility: Enclomiphene does the opposite. By stimulating LH and FSH, it keeps the testes actively producing both testosterone and sperm. The Phase III trial (Kim et al., 2016) demonstrated that sperm density was maintained (+11.7% to +15.2%) in men on enclomiphene while declining 33-57% in men on testosterone gel [6].

Important caveats:

• Preservation of sperm counts does not guarantee fertility. The FDA specifically noted that "improvement in semen parameters does not ensure fertility" [1].
• Enclomiphene has not been studied in a fertility trial with pregnancy as the endpoint.
• For men currently on TRT who want to conceive, enclomiphene or clomiphene may be used as part of a recovery protocol to restore HPG axis function and spermatogenesis, though recovery timelines are variable (typically 6-24+ months after TRT discontinuation).
• HCG remains a well-established alternative for fertility preservation during TRT, with a longer evidence base.
• Sperm banking before starting any hormonal therapy remains the most reliable fertility insurance.

Primary vs secondary hypogonadism: Men with primary hypogonadism (testicular failure) have impaired testicular function that limits both testosterone production and spermatogenesis regardless of gonadotropin stimulation. Enclomiphene will raise LH and FSH but the testes may not be able to respond adequately. These men typically require exogenous testosterone with HCG co-administration if fertility preservation is desired.

Interactions & Compatibility

Drug-drug interactions:

• Aromatase inhibitors (anastrozole, letrozole): Commonly co-prescribed to manage rising estradiol. The combination may excessively suppress E2. Monitoring is essential.
• Exogenous testosterone: Combining enclomiphene with exogenous testosterone is pharmacologically contradictory (exogenous T suppresses LH/FSH while enclomiphene tries to raise them). Some clinics use low-dose exogenous T with enclomiphene; evidence is limited.
• HCG: Can be combined with enclomiphene for additive HPG axis support. HCG stimulates the testes directly (mimicking LH), while enclomiphene works upstream at the pituitary. Limited formal study of the combination.
• 5-alpha reductase inhibitors (finasteride, dutasteride): May affect the testosterone-to-DHT conversion ratio. No specific interaction studies with enclomiphene.
• Anticoagulants: Thromboembolic events have been noted with SERM therapy; caution in patients on anticoagulants.

Supplement interactions:

• Boron: Some users combine with boron to reduce SHBG and increase free testosterone. No formal interaction data.
• DHEA: Additive androgenic effects possible. Monitor hormonal levels.
• Zinc: Supports endogenous testosterone production; no known negative interaction.
• DIM (diindolylmethane): Community-popular estrogen modulator; no formal interaction data with enclomiphene.

Lifestyle factors:

• Alcohol: Alcohol suppresses testosterone production and increases aromatization; may counteract enclomiphene's effects.
• Body composition: Higher body fat increases aromatase activity, potentially leading to greater E2 elevation. Weight loss may enhance enclomiphene's effectiveness.
• Exercise: Resistance training is synergistic with testosterone elevation from any source.
• Sleep: Critical for endogenous testosterone production; optimizing sleep may enhance enclomiphene response.

Cross-links:

• Clomiphene Citrate (Clomid) — Racemic mixture containing both enclomiphene and zuclomiphene
• HCG — Alternative fertility preservation approach
• Gonadorelin — Another HPG axis-preserving alternative
• Anastrozole (Arimidex) — Commonly co-prescribed aromatase inhibitor
• Fertility Preservation on TRT — Comprehensive fertility guide

Decision-Making Framework

Deciding whether enclomiphene is right for you requires understanding both its strengths and its genuine limitations.

Enclomiphene may be appropriate if:

• You have confirmed secondary hypogonadism (low testosterone with low or inappropriately normal LH/FSH)
• Fertility preservation is a priority (you want to maintain sperm production)
• You prefer oral medication over injections or topical applications
• You have needle aversion or skin conditions that preclude transdermal formulations
• You want to avoid the commitment of lifelong TRT (enclomiphene does not suppress the HPG axis, so discontinuation is simpler)
• You have had estrogenic side effects on clomiphene and want to try the purified isomer

Enclomiphene is likely NOT appropriate if:

• You have primary hypogonadism (the testes cannot respond to increased stimulation)
• You have Klinefelter syndrome or other testicular failure conditions
• You need reliable, well-studied symptomatic improvement (exogenous testosterone has a stronger evidence base for symptom relief)
• You have liver disease, uncontrolled thyroid/adrenal dysfunction, or pituitary tumors
• You want an FDA-approved treatment with established long-term safety data

Questions to ask your provider:

1. Is my hypogonadism primary or secondary? (This determines whether enclomiphene can work.)
2. What are my LH and FSH levels? (Low/normal LH and FSH suggest secondary hypogonadism, where enclomiphene is most effective.)
3. Is fertility important to me in the near or distant future?
4. Are you experienced in prescribing enclomiphene from compounding pharmacies?
5. What monitoring schedule will we follow?
6. At what point should we consider switching to an alternative treatment if enclomiphene is not providing symptom relief?

Finding a qualified provider: Enclomiphene is best managed by urologists with andrology training, reproductive endocrinologists, or men's health specialists who have experience with SERM therapy. The BSSM recommends that enclomiphene be prescribed by clinicians experienced in male hypogonadism, ideally within specialist or research settings [11].

The best TRT decisions happen when you walk into your appointment prepared. Doserly helps you organize your symptom data, lab results, and questions ahead of time, so you can make the most of your consultation time and ensure nothing important gets forgotten.

The app generates appointment-ready summaries of your recent symptom trends, current protocol, hematocrit and PSA values, and any side effects you've logged. Instead of trying to recall three months of experience in a ten-minute appointment, you have a clear, organized record to share with your provider.

Administration & Practical Guide

Enclomiphene is administered orally as a capsule or tablet, making it one of the simplest treatments in the male hypogonadism toolkit. No injections, no gels, no skin transfer risk, no sharps disposal.

Practical guidance:

• Take at the same time each day for consistent drug levels (morning is common)
• Can be taken with or without food (no specific food interaction data)
• Store at room temperature, away from moisture and direct light
• Compounded formulations may vary in appearance between pharmacies; this is normal
• If a dose is missed, take it when remembered unless it is close to the next scheduled dose; do not double up

Compounding pharmacy considerations:

• Enclomiphene is only available from compounding pharmacies (it is not available at retail pharmacies)
• Quality and potency may vary between compounding pharmacies
• Look for pharmacies that are 503B-outsourcing facilities (subject to FDA oversight) or 503A pharmacies with strong quality certifications (PCAB accreditation)
• Some community users have reported questionable product quality from online sources; obtaining enclomiphene through a licensed, prescription-based compounding pharmacy is recommended
• Cost varies; typical range is $50-150/month depending on pharmacy and dose

Monitoring & Lab Work

Baseline labs (before starting enclomiphene):

• Total testosterone (two morning draws, 7-10 AM)
• Free testosterone (calculated or equilibrium dialysis)
• LH and FSH (to confirm secondary hypogonadism)
• Estradiol (sensitive assay)
• SHBG
• CBC with hematocrit
• Comprehensive metabolic panel (liver function)
• Semen analysis (if fertility is a goal)
• Prolactin (if secondary hypogonadism suspected, to rule out pituitary pathology)

Initial follow-up (4-6 weeks):

• Total testosterone, free testosterone
• LH, FSH
• Estradiol
• Symptom assessment

Ongoing monitoring (every 3-6 months):

• Total testosterone, free testosterone
• Estradiol (especially if symptoms of high E2 develop)
• Hematocrit (less critical than with TRT but good practice)
• LH, FSH (to confirm ongoing response)
• Semen analysis (if fertility preservation is the primary indication)
• Liver function (periodically, given oral administration)

When to reassess the treatment plan:

• Testosterone levels not reaching target range despite dose escalation
• No symptomatic improvement after 3-6 months of adequate testosterone levels
• Rising estradiol causing symptoms (gynecomastia, fluid retention, mood changes)
• Visual disturbances (blurred vision, floaters; requires immediate evaluation)
• Desire for more reliable symptom relief (consider transitioning to TRT with fertility preservation if appropriate)

Estrogen Management on TRT

Estrogen management with enclomiphene is paradoxical. The drug itself is an estrogen receptor blocker, yet estradiol levels often rise during treatment. This happens because enclomiphene increases endogenous testosterone production, and a portion of that testosterone is converted to estradiol by the aromatase enzyme (particularly in adipose tissue).

When estrogen management matters with enclomiphene:

• Estradiol symptoms (breast tenderness, nipple sensitivity, fluid retention, mood changes) despite the SERM's receptor-blocking effects
• E2 levels rising above the reference range on lab work
• Body fat percentage is high (more aromatase activity)

The estrogen receptor blockade consideration: Because enclomiphene blocks E2 receptors, some of estrogen's beneficial effects may be reduced even when E2 levels are normal or elevated on paper. This may contribute to the "numbers vs symptoms" disconnect reported by some users. The brain, bones, and cardiovascular system all have estrogen receptors that play important roles in men's health.

AI use with enclomiphene: Some clinicians co-prescribe low-dose anastrozole (0.25-0.5 mg, 1-2 times weekly) to manage rising E2. However, the combination of an estrogen receptor blocker (enclomiphene) with an estrogen production inhibitor (anastrozole) can create a state of functional estrogen deficiency with adverse consequences including joint pain, low libido, mood disturbance, and bone density loss. If an AI is added, close monitoring of E2 levels is essential.

Community perspective: The online men's health community frequently discusses estrogen management with enclomiphene. Some users advocate for intermittent dosing (taking breaks from enclomiphene) to allow estrogen receptors to "reset" and bind with estradiol. While this approach lacks formal study, the pharmacokinetic rationale (enclomiphene's 10-hour half-life would allow receptor recovery during off days) has some theoretical basis.

Stopping TRT / Post-Cycle Considerations

One of enclomiphene's advantages is that it does not suppress the HPG axis, so discontinuation is simpler than stopping exogenous testosterone.

What happens when you stop enclomiphene:

• LH and FSH levels return to pre-treatment baseline within days to weeks
• Testosterone levels gradually decline back to pre-treatment levels over days to weeks
• The effects on LH and testosterone persist for at least 7 days after the last dose [4]
• No "crash" or withdrawal syndrome comparable to TRT discontinuation
• No PCT (post-cycle therapy) is needed because the HPG axis was never suppressed

Enclomiphene as PCT: Enclomiphene (and clomiphene) are sometimes used as part of post-cycle therapy after exogenous testosterone or anabolic steroid use. The SERM stimulates LH and FSH recovery, helping restore endogenous testosterone production. Community protocols typically use enclomiphene at 12.5-25 mg daily for 4-8 weeks during PCT.

Transitioning from enclomiphene to TRT: If enclomiphene does not provide adequate symptom relief despite normalized testosterone levels, transitioning to exogenous testosterone is straightforward. No washout period is required. Many men try enclomiphene first and transition to TRT if the symptomatic response is insufficient.

Recovery after TRT using enclomiphene: For men discontinuing TRT who want to recover natural testosterone production, enclomiphene may be used alongside HCG and/or tamoxifen. Recovery is variable (6-24+ months) and depends on duration of TRT use, age, and pre-TRT hormonal status. Recovery is not guaranteed, particularly after prolonged TRT use.

Special Populations & Situations

Young Men Desiring Fertility

Enclomiphene is most commonly discussed for men in their 20s-40s who have secondary hypogonadism and want to preserve fertility. This is the population where enclomiphene has the strongest clinical rationale. The ability to raise testosterone without suppressing spermatogenesis addresses the primary limitation of TRT in this age group.

Obese Men

Obesity-related functional hypogonadism is a common form of secondary hypogonadism. Excess adipose tissue increases aromatase activity, converting testosterone to estradiol and suppressing the HPG axis through negative feedback. A 2023 meta-analysis found that both clomiphene and enclomiphene effectively increased testosterone in men with obesity-related functional androgen deficiency, with enclomiphene increasing testosterone by a mean of 7.50 nmol/L [15]. Weight loss should be pursued concurrently, as it may resolve hypogonadism without medication.

Men with Primary Hypogonadism

Enclomiphene is not appropriate for primary hypogonadism. If the testes are unable to produce testosterone (due to Klinefelter syndrome, testicular injury, prior chemotherapy, or other causes), increasing LH and FSH will not overcome the underlying testicular failure. These men require exogenous testosterone, with HCG co-administration if fertility preservation is desired.

Men Transitioning Off TRT

Enclomiphene may help men recovering from TRT-induced HPG axis suppression. By stimulating LH and FSH, it can accelerate the recovery of endogenous testosterone production. However, recovery timelines remain variable and are not guaranteed.

Older Men (>65)

Limited data exists for enclomiphene use in older men. The clinical trials primarily enrolled men 18-60 years old. The distinction between age-related testosterone decline and true hypogonadism applies here as well. Older men may respond less robustly due to age-related Leydig cell decline.

Men on Prior Anabolic Steroid Use

Enclomiphene is increasingly used off-label for HPG axis recovery after anabolic steroid use. Response depends on the duration and severity of prior suppression and whether the testes have been permanently damaged.

Regulatory, Insurance & International

United States:

• Enclomiphene is not FDA-approved for any indication
• The FDA PCAC voted 8-4 against placing enclomiphene on the 503A Bulks List in June 2022 [1]
• Available through compounding pharmacies with a prescription (off-label)
• Not a DEA-scheduled substance
• Not covered by insurance (compounded medications are typically out-of-pocket)
• Cost: approximately $50-150/month from compounding pharmacies
• Repros Therapeutics submitted an NDA in 2015; FDA issued Complete Response Letter in December 2015; development discontinued by 2021

United Kingdom:

• Not approved by MHRA
• Available through private clinics and compounding pharmacies
• BSSM 2026 position statement recognizes enclomiphene as promising but limits recommendation to specialist settings [11]
• Not available through NHS

European Union:

• EMA assessed EnCyzix for hypogonadotropic hypogonadism in men; did not approve
• Development in Europe discontinued
• May be available through compounding pharmacies in some EU countries

Australia / Canada:

• Not approved by TGA (Australia) or Health Canada
• Limited availability through compounding or specialty import

Travel considerations:

• Enclomiphene is not a controlled substance, so travel restrictions are less stringent than for testosterone
• Carry prescription documentation when traveling internationally
• Compounded medications may require additional customs documentation

Frequently Asked Questions

Is enclomiphene the same as clomiphene (Clomid)?
No. Clomiphene contains two isomers: enclomiphene (the beneficial anti-estrogen component) and zuclomiphene (which has estrogen agonist activity and longer half-life). Enclomiphene is the isolated trans-isomer only, designed to provide the testosterone-raising effect without the estrogenic side effects of zuclomiphene.

Is enclomiphene FDA-approved?
No. Enclomiphene has never been approved by the FDA, EMA, or any major regulatory body. It is available only through compounding pharmacies with a prescription for off-label use.

Will enclomiphene work for me?
That depends on the type of hypogonadism you have. Enclomiphene works by stimulating your pituitary to produce more LH and FSH, which then stimulate your testes. If your testes are functional but your brain's signaling is the problem (secondary hypogonadism), enclomiphene can be effective. If your testes themselves are damaged (primary hypogonadism), enclomiphene will not help. A healthcare provider can determine your hypogonadism type through blood work.

Why do some people say enclomiphene raises numbers but doesn't make you feel better?
This is a genuine phenomenon reported by many users. The theory is that by blocking estrogen receptors, enclomiphene may reduce the beneficial effects of estrogen in the brain and other tissues. Since some of testosterone's mood, energy, and sexual function effects are mediated through its conversion to estradiol and binding to estrogen receptors, blocking those receptors may negate some benefits. This is an active area of discussion without definitive answers.

Can I take enclomiphene instead of TRT?
For some men with secondary hypogonadism, yes. Enclomiphene can serve as an alternative to exogenous testosterone, particularly for men who want to preserve fertility, avoid injections, or prefer not to commit to lifelong testosterone supplementation. However, if symptom relief is the primary goal, exogenous testosterone has a stronger evidence base for subjective improvement.

Does enclomiphene affect sperm count?
Clinical trials show that enclomiphene preserves or slightly increases sperm counts, in contrast to exogenous testosterone which typically suppresses sperm production. This is enclomiphene's primary clinical advantage.

What happens when I stop taking enclomiphene?
Testosterone levels gradually return to pre-treatment baseline over days to weeks. Unlike stopping TRT, there is no HPG axis suppression to recover from, so the transition is smoother.

How long can I take enclomiphene?
Unknown. No long-term safety data beyond 6 months of controlled study exists. The BSSM recommends ongoing monitoring. The decision to continue should be revisited regularly with your provider.

Is enclomiphene safe?
Short-term studies suggest a favorable safety profile with mild side effects (headache, hot flushes, nausea). Long-term safety is unknown. Concerns about chronic estrogen receptor blockade affecting bone density, cardiovascular health, and mood remain theoretical but unaddressed by clinical data.

Why didn't the FDA approve enclomiphene?
The FDA's primary concern was that clinical trials demonstrated testosterone normalization on lab tests but did not convincingly show that patients experienced meaningful improvement in hypogonadal symptoms. The FDA also raised concerns about bioanalytical methods and study design.

Myth vs. Fact

Myth: Enclomiphene is just another form of Clomid.
Fact: Enclomiphene is only one of the two isomers in clomiphene (Clomid). By isolating enclomiphene and removing zuclomiphene (which has a 30-day half-life and estrogen agonist activity), the side effect profile is significantly improved. A 2024 study found that adverse events occurred in only 13.8% of enclomiphene users versus 47% of clomiphene users [5].

Myth: If your testosterone numbers go up on enclomiphene, you should feel better.
Fact: This is not always the case. The FDA specifically found that testosterone normalization did not reliably translate to symptom improvement [1]. Many users report excellent lab numbers with limited subjective benefit. The mechanism (estrogen receptor blockade) may partially explain this disconnect.

Myth: Enclomiphene works for all types of low testosterone.
Fact: Enclomiphene only works for secondary hypogonadism (where the brain's signaling is the problem). It is ineffective for primary hypogonadism (where the testes themselves are damaged). Proper diagnosis of the type of hypogonadism is essential before starting treatment.

Myth: Enclomiphene is a steroid.
Fact: Enclomiphene is a non-steroidal selective estrogen receptor modulator (SERM). It is not an anabolic steroid, not a form of testosterone, and not a controlled substance. It works by modulating your body's own hormone signaling, not by introducing exogenous hormones.

Myth: Enclomiphene is better than TRT for everyone.
Fact: Enclomiphene has specific advantages (fertility preservation, no polycythemia risk, oral administration) but also genuine limitations (uncertain symptom relief, not FDA-approved, limited long-term data). For many men, particularly those who prioritize reliable symptom relief, exogenous testosterone remains the more evidence-supported option.

Myth: You can buy enclomiphene online without a prescription and it's the same quality.
Fact: Enclomiphene from unregulated online sources carries significant quality risks. Compounded medications from licensed pharmacies are the safest option. Some community users have reported receiving products that were mislabeled or ineffective from unregulated sources.

Myth: Enclomiphene will make you infertile.
Fact: The opposite is true. Enclomiphene preserves spermatogenesis while raising testosterone, in contrast to exogenous testosterone which typically suppresses sperm production. Fertility preservation is enclomiphene's primary clinical advantage [6].

Myth: Enclomiphene has no side effects.
Fact: While generally well-tolerated, enclomiphene can cause headache, hot flushes, nausea, and dizziness. Estradiol levels may rise over time. The theoretical risk of chronic estrogen receptor blockade on bone health and cardiovascular function is unaddressed by current research.

Sources & References

Clinical Guidelines:

1. FDA Pharmacy Compounding Advisory Committee (PCAC) Meeting Minutes and Briefing Document, June 8, 2022. Available at: https://www.fda.gov/advisory-committees/advisory-committee-calendar/june-8-2022-meeting-pharmacy-compounding-advisory-committee
2. Rodriguez KM, Pastuszak AW, Lipshultz LI. Enclomiphene citrate for the treatment of secondary male hypogonadism. Expert Opin Pharmacother. 2016;17(11):1561-1567. doi:10.1080/14656566.2016.1204294
3. Hill S, Arutchelvam AV, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12(2):109-119.
4. Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration by enclomiphene citrate in men with secondary hypogonadism: pharmacodynamics and pharmacokinetics. BJU Int. 2013;112(8):1188-1200. doi:10.1111/bju.12363

Clinical Trials:
5. Saffati G, Kassab J, Rendon DO, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol. 2024;13(9):1984-1990. doi:10.21037/tau-24-238
6. Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. doi:10.1111/bju.13337
7. Repros Therapeutics Announces Receipt of Complete Response Letter from FDA for Enclomiphene. December 2015. Available at: https://www.drugs.com/nda/androxal_151029.html

Systematic Reviews & Meta-Analyses:
8. Huang ES, Miller WL. Estrogenic and antiestrogenic effects of enclomiphene and zuclomiphene on gonadotropin secretion by ovine pituitary cells in culture. Endocrinology. 1983;112(2):442-448.
9. Earl JA, Kim ED. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157-165.
10. Wiehle RD, et al. Enclomiphene citrate stimulates serum testosterone in men with low testosterone within 14 days. J Men's Health. 2014;11(4):196-205.
11. Foster J, Choo L, Patel A, Kirby M, Hackett G. British Society of Sexual Medicine: Position Statement for the Potential Use of Enclomiphene in the Treatment of Male Hypogonadism. World J Mens Health. 2026. doi:10.5534/wjmh.250395
12. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab. 2025;69(5):e250093.
13. Wiehle RD, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-727.

Landmark Trial Data:
14. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025 (TRAVERSE trial)

Other:
15. Tienforti D, Castellini C, Di Giulio F, et al. Selective modulation of estrogen receptor in obese men with androgen deficiency: A systematic review and meta-analysis. Andrology. 2023;11(5):1067-1076. doi:10.1111/andr.13373

Related Guides & Cross-Links

Same Category (Ancillary: Fertility & HPG Axis)

• Clomiphene Citrate (Clomid) — Racemic mixture containing enclomiphene + zuclomiphene
• Human Chorionic Gonadotropin (HCG) — Alternative fertility preservation approach
• Gonadorelin — GnRH agonist for HPG axis support

Related Treatment Options

• Tamoxifen (Nolvadex) — Alternative SERM used in PCT
• Anastrozole (Arimidex) — AI commonly co-prescribed with enclomiphene
• Fertility Preservation on TRT — Comprehensive guide to maintaining fertility during testosterone therapy

Condition Guides

• Secondary Hypogonadism — The condition enclomiphene primarily treats
• Obesity-Related Hypogonadism — Common indication for SERM therapy

Treatment Overviews

• TRT for Beginners — Starting guide for men new to testosterone therapy
• Stopping TRT & Post-Cycle Recovery — Enclomiphene's role in recovery